MAGNESIUM SULFATE

Magnesium Sulfate Adverse Events Reported to the FDA Over Time

How are Magnesium Sulfate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Magnesium Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Magnesium Sulfate is flagged as the suspect drug causing the adverse event.

Most Common Magnesium Sulfate Adverse Events Reported to the FDA

What are the most common Magnesium Sulfate adverse events reported to the FDA?

Drug Exposure During Pregnancy	95 (5.87%)
Medication Error	46 (2.84%)
Caesarean Section	25 (1.54%)
Hypocalcaemia	24 (1.48%)
Tachycardia Foetal	24 (1.48%)
Premature Baby	23 (1.42%)
Drug Ineffective	22 (1.36%)
Foetal Distress Syndrome	21 (1.3%)
Drug Interaction	20 (1.24%)
Hypermagnesaemia	20 (1.24%)
Hypotension	19 (1.17%)
	Show More
Blood Magnesium Increased	15 (.93%)
Maternal Drugs Affecting Foetus	15 (.93%)
Neonatal Disorder	15 (.93%)
Osteopenia	15 (.93%)
Dyspnoea	14 (.86%)
Malaise	14 (.86%)
Blood Alkaline Phosphatase Increase...	13 (.8%)
Toxic Epidermal Necrolysis	13 (.8%)
Cardiac Arrest	12 (.74%)
Nausea	12 (.74%)
Respiratory Failure	12 (.74%)
Drug Dispensing Error	11 (.68%)
Incorrect Dose Administered	11 (.68%)
Neuromuscular Blockade	11 (.68%)
Oxygen Saturation Decreased	11 (.68%)
Apgar Score Low	9 (.56%)
Condition Aggravated	9 (.56%)
Grand Mal Convulsion	9 (.56%)
Pre-eclampsia	9 (.56%)
Vomiting	9 (.56%)
Convulsion	8 (.49%)
Depressed Level Of Consciousness	8 (.49%)
Drug Exposure Via Breast Milk	8 (.49%)
Drug Toxicity	8 (.49%)
Infusion Related Reaction	8 (.49%)
Pulmonary Oedema	8 (.49%)
Somnolence	8 (.49%)
Unresponsive To Stimuli	8 (.49%)
Accidental Overdose	7 (.43%)
Asthma	7 (.43%)
Blood Glucose Increased	7 (.43%)
Blood Pressure Decreased	7 (.43%)
Blood Pressure Increased	7 (.43%)
Chest Discomfort	7 (.43%)
Coma	7 (.43%)
Diarrhoea	7 (.43%)
Hypertension	7 (.43%)
Loss Of Consciousness	7 (.43%)
Neuromuscular Block Prolonged	7 (.43%)
Pneumonia	7 (.43%)
Tremor	7 (.43%)
Apallic Syndrome	6 (.37%)
Blood Calcium Decreased	6 (.37%)
Bradycardia	6 (.37%)
Cerebrovascular Disorder	6 (.37%)
Circumstance Or Information Capable...	6 (.37%)
Completed Suicide	6 (.37%)
Death	6 (.37%)
Dizziness	6 (.37%)
Hyperhidrosis	6 (.37%)
Overdose	6 (.37%)
Premature Labour	6 (.37%)
Procedural Hypotension	6 (.37%)
Pulmonary Interstitial Emphysema Sy...	6 (.37%)
Pyrexia	6 (.37%)
Renal Impairment	6 (.37%)
Rib Fracture	6 (.37%)
Urticaria	6 (.37%)
Ventricular Tachycardia	6 (.37%)
Asthenia	5 (.31%)
Chest Pain	5 (.31%)
Disseminated Intravascular Coagulat...	5 (.31%)
Feeling Hot	5 (.31%)
Flushing	5 (.31%)
Heart Rate Increased	5 (.31%)
Intra-uterine Death	5 (.31%)
Multi-organ Failure	5 (.31%)
Muscle Spasms	5 (.31%)
Neonatal Respiratory Distress Syndr...	5 (.31%)
Respiratory Arrest	5 (.31%)
Respiratory Depression	5 (.31%)
Respiratory Distress	5 (.31%)
Respiratory Rate Decreased	5 (.31%)
Urine Output Decreased	5 (.31%)
Wrong Drug Administered	5 (.31%)
Anaemia	4 (.25%)
Cardiovascular Disorder	4 (.25%)
Congenital Anomaly	4 (.25%)
Congenital Musculoskeletal Anomaly	4 (.25%)
Craniotabes	4 (.25%)
Drug Administration Error	4 (.25%)
Dysarthria	4 (.25%)
Electrocardiogram Qt Prolonged	4 (.25%)
Encephalopathy	4 (.25%)
Fatigue	4 (.25%)
Gait Disturbance	4 (.25%)
Headache	4 (.25%)
Hepatic Enzyme Increased	4 (.25%)
Hypersensitivity	4 (.25%)
Hypotonia Neonatal	4 (.25%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Magnesium Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Magnesium Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Magnesium Sulfate

What are the most common Magnesium Sulfate adverse events reported to the FDA?

Chemical Injury And Poisoning	120 (7.41%)
Medication Errors	114 (7.04%)
Neurological	89 (5.5%)
Cardiac Arrhythmias	85 (5.25%)
Respiratory	65 (4.01%)
Bone, Calcium, Magnesium And Phosph...	52 (3.21%)
Therapeutic And Nontherapeutic Effe...	49 (3.03%)
Neonatal And Perinatal Conditions	42 (2.59%)
Epidermal And Dermal Conditions	35 (2.16%)
Cardiac And Vascular Investigations	33 (2.04%)
Gastrointestinal Signs	30 (1.85%)
	Show More
Water, Electrolyte And Mineral	30 (1.85%)
Fetal Complications	29 (1.79%)
Infections - Pathogen Unspecified	28 (1.73%)
Obstetric And Gynecological Therape...	26 (1.61%)
Bone And Joint Injuries	25 (1.54%)
Metabolic, Nutritional And Blood Ga...	25 (1.54%)
Procedural And Device Related Injur...	25 (1.54%)
Lower Respiratory Tract Disorders	24 (1.48%)
Bone Disorders	20 (1.24%)
Decreased And Nonspecific Blood Pre...	20 (1.24%)
Seizures	18 (1.11%)
Physical Examination Topics	17 (1.05%)
Maternal Complications Of Pregnancy	15 (.93%)
Enzyme	14 (.86%)
Gastrointestinal Motility And Defec...	14 (.86%)
Movement Disorders	14 (.86%)
Neuromuscular	14 (.86%)
Administration Site Reactions	13 (.8%)
Central Nervous System Vascular	13 (.8%)
Muscle	13 (.8%)
Bacterial Infectious	12 (.74%)
Bronchial Disorders	12 (.74%)
Allergic Conditions	11 (.68%)
Maternal Complications Of Labour An...	11 (.68%)
Vascular	11 (.68%)
Hepatobiliary	10 (.62%)
Musculoskeletal And Connective Tiss...	10 (.62%)
Cardiac Disorder Signs	9 (.56%)
Hematology Investigations	9 (.56%)
Angiedema And Urticaria	8 (.49%)
Neonatal Respiratory	8 (.49%)
Placental, Amniotic And Cavity Diso...	8 (.49%)
Renal And Urinary Tract Investigati...	8 (.49%)
Renal Disorders	8 (.49%)
Fatal Outcomes	7 (.43%)
Myocardial	7 (.43%)
Pregnancy, Labour, Delivery And Pos...	7 (.43%)
Skin Appendage Conditions	7 (.43%)
Vascular Hypertensive	7 (.43%)
Acid-base	6 (.37%)
Anemias Nonhemolytic And Marrow Dep...	6 (.37%)
Appetite And General Nutritional	6 (.37%)
Body Temperature Conditions	6 (.37%)
Coagulopathies And Bleeding Diathes...	6 (.37%)
Congenital And Hereditary	6 (.37%)
Coronary Artery	6 (.37%)
Encephalopathies	6 (.37%)
Musculoskeletal And Connective Tiss...	6 (.37%)
Musculoskeletal And Connective Tiss...	6 (.37%)
Ocular Neuromuscular	6 (.37%)
Suicidal And Self-injurious Behavio...	6 (.37%)
Abortions And Stillbirth	5 (.31%)
Ear And Labyrinthine Disorders Cong...	5 (.31%)
Electrolyte And Fluid Balance Condi...	5 (.31%)
Gastrointestinal Tract Disorders Co...	5 (.31%)
Oral Soft Tissue Conditions	5 (.31%)
Product Quality Issues	5 (.31%)
Vision	5 (.31%)
Cardiac Valve	4 (.25%)
Gallbladder	4 (.25%)
Gastrointestinal Hemorrhages	4 (.25%)
Headaches	4 (.25%)
Hypothalamus And Pituitary Gland	4 (.25%)
Injuries	4 (.25%)
Psychiatric	4 (.25%)
Therapeutic Procedures And Supporti...	4 (.25%)
Upper Respiratory Tract Disorders	4 (.25%)
Deliria	3 (.19%)
Embolism And Thrombosis	3 (.19%)
Gastrointestinal Inflammatory Condi...	3 (.19%)
Hematological And Lymphoid Tissue T...	3 (.19%)
Hepatic And Hepatobiliary	3 (.19%)
Joint	3 (.19%)
Lipid Analyses	3 (.19%)
Mental Impairment	3 (.19%)
Neurological Disorders Congenital	3 (.19%)
Peritoneal And Retroperitoneal Cond...	3 (.19%)
Tongue Conditions	3 (.19%)
Viral Infectious	3 (.19%)
Anal And Rectal Conditions	2 (.12%)
Aneurysms And Artery Dissections	2 (.12%)
Anxiety Disorders	2 (.12%)
Arteriosclerosis, Stenosis, Vascula...	2 (.12%)
Benign Neoplasms Gastrointestinal	2 (.12%)
Cardiac And Vascular Disorders Cong...	2 (.12%)
Endocrine Investigations	2 (.12%)
Fetal And Neonatal	2 (.12%)
Gastrointestinal	2 (.12%)
Gastrointestinal Vascular Condition...	2 (.12%)
Heart Failures	2 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Magnesium Sulfate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Magnesium Sulfate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.